

## News Release



January 28, 2026  
JCR Pharmaceuticals Co., Ltd.

### Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2026

**Hyogo, Japan – January 28, 2026 – [JCR Pharmaceuticals Co., Ltd.](#)** (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that the Company made the following revisions to the consolidated earnings forecasts for the fiscal year ended March 31, 2026 disclosed on May 13, 2025 (at the time of the financial results announcement) based on the current business performance.

There are no changes to the previously announced dividend forecast.

#### 1. Revision of consolidated financial forecasts for the fiscal year ended March 31, 2026

(Unit: Millions of yen)

	Net Sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share (yen)
Previously announced forecasts (A)	37,800	2,600	2,400	3,000	24.22
Revised forecasts (B)	39,500	400	400	1,600	13.12
Change (B-A)	1,700	(2,200)	(2,000)	(1,400)	—
Change (%)	4.5 %	(84.6) %	(83.3) %	(46.7) %	—
Actual Results of the previous fiscal year	33,072	(6,650)	(7,477)	(4,759)	(38.43)

#### 2. Reason for the revision

Net sales are forecast at 39,500 million yen, up 1,700 million yen from the previous projection, mainly reflecting stronger-than-expected sales of products for renal anemia and Fabry disease. Details are provided in the appendix.

Cost of sales is projected to increase by 1,200 million yen due to increased sales and changes in the product mix.

R&D expenses have been revised upward by 1,500 million yen, reflecting recognition of an upfront payment in the third quarter related to the exclusive givinostat license acquired from Italfarmaco S.p.A. in December 2025 for Japan.

Selling, general and administrative expenses have been revised upward by 1,200 million yen, reflecting recognition of depreciation incurred prior to the confirmation of subsidies for the Kobe Science Park Center (API facility), as well as year-to-date performance through the third quarter.

As a result, operating profit has been revised down by 2,200 million yen to 400 million yen. Ordinary profit was revised down by 2,000 million yen to 400 million yen, and net profit attributable to owners of the parent was reduced by 1,400 million yen to 1,600 million yen.

<Appendix>

The revised forecast breaks down of product sales.

(Unit: Millions of yen)

	Previously announced forecasts (A)	Revised forecasts (B)	Change (B-A)	Change (%)	(Reference) Actual results of the previous fiscal year
GROWJECT™	17,800	17,800	—	—	18,098
IZCARGO™	6,400	6,400	—	—	5,718
TEMCELL™ HS Inj.	2,700	2,700	—	—	2,904
Treatments for renal Anemia	3,100	3,600	500	16.1 %	3,784
Epoetin Alfa BS Inj. [JCR]	800	1,100	300	37.5 %	1,690
Darbepoetin Alfa BS Inj. [JCR]	2,300	2,500	200	8.7 %	2,093
Agalsidase Beta BS I.V. Infusion [JCR]	1,100	1,600	500	45.5 %	1,149
Total pharmaceutical products	31,100	32,100	1,000	3.2 %	31,655
License Revenue	5,500	5,800	300	5.5 %	517
Other	1,200	1,600	400	33.3 %	898
Total Net Sales	37,800	39,500	1,700	4.5 %	33,072

Note: The forecasts above are based on information available as of the announcement date and are subject to change due to various factors.

**About JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: <https://jcrpharm.com/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###